The multifaceted circulating endothelial cell in cancer: Towards marker and target identification

Francesco Bertolini, Yuval Shaked, Patrizia Mancuso, Robert S. Kerbel

Research output: Contribution to journalArticlepeer-review

Abstract

Increases in the number of circulating endothelial cells (CECs) and progenitors (CEPs) have been reported in various pathological conditions including cancer. Preclinical studies have shown that CEC and CEP kinetics correlate well with several standard laboratory angiogenesis assays, which cannot be used in humans. At the clinical level, evidence is emerging that CEC kinetics and viability might correlate with clinical outcomes in cancer patients who undergo anti-angiogenic treatment. Therefore, CEC and CEP measurement has potential as a surrogate marker for monitoring anti-angiogenic treatment and drug activity, and could help to determine the optimal biological dose of anti-angiogenic drugs, which are being used with increasing frequency in medical oncology.

Original languageEnglish
Pages (from-to)835-845
Number of pages11
JournalNature Reviews Cancer
Volume6
Issue number11
DOIs
Publication statusPublished - Nov 12 2006

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'The multifaceted circulating endothelial cell in cancer: Towards marker and target identification'. Together they form a unique fingerprint.

Cite this